Latest News in the pharma Industry

Research & Development

Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes

Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes

28 Apr 2016

Subject to approvals, Ilaris will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF.

Read more 
If radiotherapy hurts your skin, it’s genetic

If radiotherapy hurts your skin, it’s genetic

28 Apr 2016

New gene discovery could mean more personalised cancer care.

Read more 
Chantix/Champix results from the largest global clinical trial of smoking cessation medicines published in The Lancet

Chantix/Champix results from the largest global clinical trial of smoking cessation medicines published in The Lancet

25 Apr 2016

Authors conclude no significant increase in serious neuropsychiatric adverse events with Chantix/Champix relative to placebo or nicotine patch.

Read more 
BMS's Opdivo receives Breakthrough Therapy Designation from FDA for previously treated recurrent or metastatic squamous cell carcinoma of the head and neck

BMS's Opdivo receives Breakthrough Therapy Designation from FDA for previously treated recurrent or metastatic squamous cell carcinoma of the head and neck

25 Apr 2016

Designation signals the urgent need for new treatment approaches in recurrent or metastatic squamous cell carcinoma of the head and neck after platinum based therapy.

Read more 
Novartis drug Afinitor significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex

Novartis drug Afinitor significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex

21 Apr 2016

Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients.

Read more 
Presage Biosciences presents data demonstrating superior tumour growth inhibition by voruciclib and proteasome inhibitors

Presage Biosciences presents data demonstrating superior tumour growth inhibition by voruciclib and proteasome inhibitors

20 Apr 2016

Data presented at AACR Annual Meeting from CIVO platform.

Read more 
NIH study finds factors that may influence influenza vaccine effectiveness

NIH study finds factors that may influence influenza vaccine effectiveness

20 Apr 2016

Neuraminidase, which is not currently the main target antigen in traditional flu vaccines, enables newly formed flu viruses to exit the host cell and cause further viral replication in the body.

Read more 
Jardiance to be studied for the treatment of people with chronic heart failure

Jardiance to be studied for the treatment of people with chronic heart failure

19 Apr 2016

The trials are targeted to begin within the next 12 months and are planned to enroll people with chronic heart failure both with and without type 2 diabetes.

Read more 
New survival data for nivolumab in head and neck cancer

New survival data for nivolumab in head and neck cancer

19 Apr 2016

Phase III data for nivolumab in head and neck cancer show biggest increase in survival for 20 years.

Read more 
Protein research offers ”promising” potential treatment of Alzheimer’s disease

Protein research offers ”promising” potential treatment of Alzheimer’s disease

19 Apr 2016

Read more 
Innovations in proteomics and genomics drive era of precision medicine

Innovations in proteomics and genomics drive era of precision medicine

18 Apr 2016

Broad spectrum of technological advances for cancer research on display at AACR 2016.

Read more 
Seattle Genetics highlights novel ADC technology advances at AACR

Seattle Genetics highlights novel ADC technology advances at AACR

18 Apr 2016

Innovative research demonstrates Seattle Genetics’ leadership in empowered antibodies.

Read more